Bimekizumab's Favorable Safety Profile in Psoriasis A 2-year safety study of BMK, the dual IL-17A/F inhibitor, plaque psoriasis patients showed BMK, to be effective, well tolerated, w/ no new safety concerns other than a modest risk of oral candidiasis. https://t.co/84zS8VET6B https://t.co/aLvLmmTc93